Compare AMETEK, Inc. (AME) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Neurocrine Biosciences Inc — how do they compare? AMETEK, Inc. trades at $255.78 (market cap $58.76B), while Neurocrine Biosciences Inc trades at $151.61 (market cap $16.46B). The key difference: AMETEK, Inc. is far larger — about 3.6× Neurocrine Biosciences Inc's market cap, and AMETEK, Inc. pays a 0.53% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| AME | NBIX | |
|---|---|---|
Market Cap | $58.76B | $16.46B |
Sector | Industrials | Health |
52-Week High | $256.30 | $185.50 |
52-Week Low | $179.28 | $123.10 |
Enterprise Value | $60.30B | $16.48B |
Dividend Yield | 0.53% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
